Mucpharm Pty Ltd Report issue

For profit Phase 2
Founded: London United Kingdom (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2019
NCT03976973
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

David Morris | Mucpharm Pty Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylcysteine (mucomyst) (2 trials)

anacaulase (NexoBrid) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Mucinous (Phase 2)

Cystadenocarcinoma (Phase 2)

Pseudomyxoma Peritonei (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2